Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 17, 2013, Pages 2315-2322

  Ohta, Akio ^a   Ohshige, Toshihiko ^a   Sakai, Kensuke ^a   Nakamura, Yuta ^a   Tenjin, Ayumi ^a   Tsukiyama, Shuichi ^a   Terashima, Yuko ^a   Matsubara, Fumiaki ^a   Kawata, Takehiro ^a   Nagai, Yoshio ^a   Tanaka, Yasushi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1,5 anhydroglucitol; Glycoalbumin; Mitiglinide; Sitagliptin; Voglibose

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; MITIGLINIDE; SITAGLIPTIN; VOGLIBOSE;

ABDOMINAL PAIN; AGED; ARTICLE; BLOATING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESPONSE; JAPANESE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TEST MEAL; TREATMENT DURATION; WEIGHT CHANGE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CROSS-OVER STUDIES; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; ISOINDOLES; MALE; MIDDLE AGED; PYRAZINES; SERUM ALBUMIN; TRIAZOLES;

EID: 84887869384     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.842554     Document Type: Article

References (31)

1. Del Prato S, Tiengo A. The importance of first-phase insulin secretion: Implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001;17:164-74
2. Tanaka Y, Atsumi Y, Asahina T, et al. Usefulness of revised fasting plasma glucose criterion and characteristics of the insulin response to an oral glucose load in newly diagnosed Japanese diabetic subjects. Diabetes Care 1998;21:1133-7
3. DECODE Study Group. Glucose tolerance and mortality: Comparison of WHO an American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21
4. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
5. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003;290:486-94
6. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-Analysis of seven long-Term studies. Eur Heart J 2004;25:10-16
7. Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007;27:2456-62
8. Kataoka Y, Yasuda S, Miyamoto Y, et al. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J 2012;76:712-20
9. Monami M, Ahrén B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-Analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-20
10. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
11. Ono Y, Kameda H, Cho KY. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2013;14:361-70
12. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
13. Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/ insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:500-3
14. Sunaga Y, Gonoi T, Shibasaki T, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: Comparison with the sulfonylureas and nateglinide. Eur J Pharmacol 2001;431:119-25
15. Shigeto M, Katsura M, Matsuda M, et al. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther 2007;322:1-7
16. Kaiser N, Nesher R, Oprescu A, et al. Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells. Br J Pharmacol 2005;146:872-81
17. Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res 2009;37:1904-12
18. Ward WK, Bolgiano DC, McKnight B, et al. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984;74:1318-28
19. Kitasato L, Tojo T, Hatakeyama Y, et al. Postprandial hyperglycemia and endothelial function in type 2 diabetes: Focus on mitiglinide. Cardiovasc Diabetol 2012;11:1-9
20. Uchino H, Niwa M, Shimizu T, et al. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: Assessment using nateglinide, a new insulin secretagogue. Endocr J 2000;47:639-41
21. Standl E, Schnell O. Alpha-glucosidase inhibitors 2012-cardiovascular considerations and trial evaluation. Diab Vasc Dis Res 2012;9:163-9
22. Derosa G, Maffioli P. a-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 2012;9:899-906
23. Inoue M. Tighter control of postprandial hyperglycaemia with mitiglinide/ voglibose fixed-dose combination in patients with type 2 diabetes. Expert Opin Pharmacother 2012;13:2257-68
24. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyzes gastric-inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidinemethionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829-35
25. Muscelli E, Casolaro A, Gastaldelli A, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97:2818-26
26. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type2 diabetes. Curr Med Res Opin 2007;23:1329-39
27. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383-94
28. Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-8
29. Yamanouchi T, Ogata N, Tagaya T, et al. Clinical usefulness of serum 1,5-Anhydroglucitol in monitoring glycaemic control. Lancet 1996;347:1514-18
30. Takahashi S, Uchino H, Shimizu T, et al. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: Usefulness of GA for evaluation of short-Term changes in glycemic control. Endocr J 2007;54:139-44
31. Suwa T, Ohta A, Matsui T, et al. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J 2010;57:135-40